Unknown

Dataset Information

0

Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus.


ABSTRACT: Current guidelines encourage administering pneumococcal vaccine Prevnar-13 to patients with lupus, but whether such vaccinations affect disease severity is unclear. To address this issue, we treated 3-month-old MRL-lpr mice, that spontaneously develop a lupus-like syndrome, with Prevnar-13 or vehicle control. After 3 months, we quantified circulating anti-Pneumococcal polysaccharide capsule (PPS) antibodies and signs of disease severity, including albuminuria, renal histology and skin severity score. We also compared immunophenotypes and function of T and B cells from treated and untreated animals. Prevnar-13 elicited the formation of anti-pneumococcal IgM and IgG. Prevnar-13 treated animals showed reduced albuminuria, renal histological lesions, and milder dermatitis compared to vehicle-treated controls. Mitigated disease severity was associated with reduced and increased T follicular helper cells (TFH) and T follicular regulatory cells (TFR), respectively, in Prevnar-treated animals. T cells from Prevnar-13 vaccinated mice showed differential cytokine production after aCD3/aCD28 stimulation, with significantly decreased IL-17 and IL-4, and increased IL-10 production compared to non-vaccinated mice. In conclusion, pneumococcal vaccination elicits anti-pneumococcal antibody response and ameliorates disease severity in MRL-lpr mice, which associates with fewer TFH and increased TFR. Together, the data support use of Prevnar vaccination in individuals with SLE.

SUBMITTER: Cantarelli C 

PROVIDER: S-EPMC6879550 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications


Current guidelines encourage administering pneumococcal vaccine Prevnar-13 to patients with lupus, but whether such vaccinations affect disease severity is unclear. To address this issue, we treated 3-month-old MRL-<i>lpr</i> mice, that spontaneously develop a lupus-like syndrome, with Prevnar-13 or vehicle control. After 3 months, we quantified circulating anti-Pneumococcal polysaccharide capsule (PPS) antibodies and signs of disease severity, including albuminuria, renal histology and skin sev  ...[more]

Similar Datasets

| S-EPMC8073120 | biostudies-literature
| S-EPMC7684155 | biostudies-literature
| S-EPMC3008188 | biostudies-literature
| S-EPMC6988977 | biostudies-literature
| S-EPMC5195893 | biostudies-literature
| S-EPMC4899320 | biostudies-literature
| S-EPMC7510723 | biostudies-literature
| S-EPMC1123818 | biostudies-literature
| S-EPMC3135348 | biostudies-literature
| S-EPMC6605723 | biostudies-literature